Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2007

01.02.2007

Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

verfasst von: Dario Baratti, MD, Shigeki Kusamura, MD, Antonia Martinetti, MD, Ettore Seregni, MD, Daniela G. Oliva, MD, Barbara Laterza, MD, Marcello Deraco, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent phase I/II trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with PM undergoing CRS and IPHP.

Methods

Clinical data on 60 patients with PM operated with the intention to perform adequate CRS (residual tumor nodules ≤ 2.5mm) and IPHP were prospectively collected. Marker levels were determined pre-operatively, post-operatively, and routinely during long-term follow-up. Baseline diagnostic sensitivity, accuracy in monitoring response to treatment or tumor progression and prognostic significance were determined.

Results

Baseline diagnostic sensitivity was 53.3% for CA125, 0 for CEA, 3.8% for CA19.9 and 48.5% for CA15.3. Forty-six patients underwent adequate cytoreduction and IPHP; gross residual tumor was left after the operation in fourteen. Postoperatively, CA125 became negative in 21/22 patients with elevated baseline levels undergoing adequate CRS and IPHP, while remained elevated in 9/9 patients with persistent macroscopic disease. CA125 became positive in 12/12 patients with elevated baseline levels developing disease progression after adequate CRS and IPHP. Baseline CA125 showed borderline prognostic significance only among patients not previously treated with systemic chemotherapy.

Conclusions

CA125 was elevated in the majority of patients with PM in the present series. Serial maker measurements paralleled tumor growth or regression after CRS and IPHP, suggesting the need of further studies to assess the role of CA125 in this clinical setting.
Literatur
1.
Zurück zum Zitat Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. JCO 1988; 6:147–153 Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. JCO 1988; 6:147–153
2.
Zurück zum Zitat Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356–362PubMedCrossRef Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356–362PubMedCrossRef
3.
Zurück zum Zitat Eltabbakh GH, Piver MS, Hempling RE. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6–12PubMedCrossRef Eltabbakh GH, Piver MS, Hempling RE. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6–12PubMedCrossRef
4.
Zurück zum Zitat Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am 2003; 12:703–727CrossRef Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am 2003; 12:703–727CrossRef
5.
Zurück zum Zitat Stewart JH, Perry S, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy:current status and future directions. Ann Surg Oncol 2005; 12:765–777PubMedCrossRef Stewart JH, Perry S, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy:current status and future directions. Ann Surg Oncol 2005; 12:765–777PubMedCrossRef
6.
Zurück zum Zitat Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83:147–53PubMedCrossRef Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83:147–53PubMedCrossRef
7.
Zurück zum Zitat Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6:582–590PubMedCrossRef Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6:582–590PubMedCrossRef
8.
Zurück zum Zitat Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87:1587–1593PubMedCrossRef Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87:1587–1593PubMedCrossRef
9.
Zurück zum Zitat Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999–1003PubMed Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999–1003PubMed
10.
Zurück zum Zitat Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003; 12:605–621CrossRef Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003; 12:605–621CrossRef
11.
Zurück zum Zitat Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–4567PubMedCrossRef Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–4567PubMedCrossRef
12.
Zurück zum Zitat Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum. Cancer 2005; 104:2181–2188PubMedCrossRef Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum. Cancer 2005; 104:2181–2188PubMedCrossRef
13.
Zurück zum Zitat Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405–412PubMedCrossRef Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405–412PubMedCrossRef
14.
Zurück zum Zitat Bagshawe KD, Rustin GJ. (1995) Circulating tumour markers. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford University Press, Oxford, UK, pp 412–420 Bagshawe KD, Rustin GJ. (1995) Circulating tumour markers. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford University Press, Oxford, UK, pp 412–420
15.
Zurück zum Zitat Weiss SW. World Health Organization Istological Classification of tomors. Histological typing of soft tissue tumours. 2nd edition. Berlin: Springer-Verlag, 1994 Weiss SW. World Health Organization Istological Classification of tomors. Histological typing of soft tissue tumours. 2nd edition. Berlin: Springer-Verlag, 1994
16.
Zurück zum Zitat Oken MM, Creech RH, Tormey, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655 Oken MM, Creech RH, Tormey, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655
17.
Zurück zum Zitat Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321–325 Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321–325
18.
Zurück zum Zitat Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58 Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58
19.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRef
20.
Zurück zum Zitat Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457–481 Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457–481
21.
Zurück zum Zitat Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220 Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220
22.
Zurück zum Zitat Hayes AJ, Mostyn-Jones A, Koban MU, et al. Serum vascolar growth factor as a tumor marker in soft tissue sarcoma. Br J Surg 2004; 91:242–247PubMedCrossRef Hayes AJ, Mostyn-Jones A, Koban MU, et al. Serum vascolar growth factor as a tumor marker in soft tissue sarcoma. Br J Surg 2004; 91:242–247PubMedCrossRef
23.
Zurück zum Zitat Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362:1612–1616PubMedCrossRef Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362:1612–1616PubMedCrossRef
24.
Zurück zum Zitat Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma and serum osteopontin level. N Engl J Med 2005; 353:1564–1573PubMedCrossRef Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma and serum osteopontin level. N Engl J Med 2005; 353:1564–1573PubMedCrossRef
25.
Zurück zum Zitat Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronian and CA125 as serum markers in malignant mesothelioma. Anticancer Res 2003, 23:531–536PubMed Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronian and CA125 as serum markers in malignant mesothelioma. Anticancer Res 2003, 23:531–536PubMed
26.
Zurück zum Zitat Simsek H, Kadayifci A, Okan E. Importance of serum CA125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996; 17:1–4PubMedCrossRef Simsek H, Kadayifci A, Okan E. Importance of serum CA125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996; 17:1–4PubMedCrossRef
27.
Zurück zum Zitat Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331–1337PubMedCrossRef Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331–1337PubMedCrossRef
28.
Zurück zum Zitat Rustin GJS, Timmers P, Nelstrop P, Shreeves G, Bentzen SM, Baron B, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide Journal of Clinical Oncology 2006; 24:45–51PubMedCrossRef Rustin GJS, Timmers P, Nelstrop P, Shreeves G, Bentzen SM, Baron B, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide Journal of Clinical Oncology 2006; 24:45–51PubMedCrossRef
29.
Zurück zum Zitat Kerin MJ, McAnena OJ, O’Malley VP, et al. CA15–3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76:838–839PubMedCrossRef Kerin MJ, McAnena OJ, O’Malley VP, et al. CA15–3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76:838–839PubMedCrossRef
30.
Zurück zum Zitat Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22:1203–1214PubMedCrossRef Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22:1203–1214PubMedCrossRef
31.
Zurück zum Zitat Bateman AC, al-Talib RK, Newman Y, et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997; 30:49–56PubMedCrossRef Bateman AC, al-Talib RK, Newman Y, et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997; 30:49–56PubMedCrossRef
32.
Zurück zum Zitat Duan HJ, Itoh N, Yamagami O, et al. Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125. Acta Pathol Jpn 1991; 41:158–163PubMed Duan HJ, Itoh N, Yamagami O, et al. Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125. Acta Pathol Jpn 1991; 41:158–163PubMed
33.
Zurück zum Zitat Almudevar Bercero E, Garcia-Rostan Perez GM, Garcia Bragado F, et al. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31:267–273PubMedCrossRef Almudevar Bercero E, Garcia-Rostan Perez GM, Garcia Bragado F, et al. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31:267–273PubMedCrossRef
34.
Zurück zum Zitat Kebapci M, Vardareli E, Adapinar B, et al. CT findings and serum CA125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620–2626PubMedCrossRef Kebapci M, Vardareli E, Adapinar B, et al. CT findings and serum CA125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620–2626PubMedCrossRef
35.
Zurück zum Zitat Begent R, Rustin GJ. Tumour markers: from carcinoembryonic antigen to products of hybridoma technology. Cancer Surv 1989; 8:107–21PubMed Begent R, Rustin GJ. Tumour markers: from carcinoembryonic antigen to products of hybridoma technology. Cancer Surv 1989; 8:107–21PubMed
36.
Zurück zum Zitat Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961–967PubMedCrossRef Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961–967PubMedCrossRef
37.
Zurück zum Zitat Garcia-Carbonero R, Paz-Arez L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676–681PubMedCrossRef Garcia-Carbonero R, Paz-Arez L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676–681PubMedCrossRef
Metadaten
Titel
Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
verfasst von
Dario Baratti, MD
Shigeki Kusamura, MD
Antonia Martinetti, MD
Ettore Seregni, MD
Daniela G. Oliva, MD
Barbara Laterza, MD
Marcello Deraco, MD
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9192-8

Weitere Artikel der Ausgabe 2/2007

Annals of Surgical Oncology 2/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.